Ensysce Biosciences Inc — Cash Flow (NASDAQ:ENSC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -864.44 K-8.24 M-17.89 M-10.78 M-7.5 M -7.04 M Cash from investing activities 183.4 M—4 5000— — Cash from financing activities -183.55 M20.31 M8.77 M8.76 M9.88 M 4.69 M Free cash flow -864.44 K-8.24 M-17.89 M-10.78 M-7.5 M -7.04 M

News

Ensysce publishes phase 1 data on overdose-limiting opioid tech

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.05%

Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Ensysce Biosciences (NASDAQ:ENSC)

Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial

Ensysce Biosciences receives patent allowance in Brazil for pain tech

Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript

Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid

Ensysce Biosciences enrolls first patient in phase 3 pain drug trial

Ensysce Biosciences Narrows Loss in Q2

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

ensysce biosciences appoints baker tilly as new auditor